title: Pyridinyl polythiazole class peptide antibiotic micrococcin P1, secreted by foodborne Staphylococcus equorum WS2733, is biosynthesized nonribosomally.
abstract: Recently, foodborne Staphylococcus equorum WS2733 was isolated from a French red smear cheese on account of its strong inhibitory activity against Gram-positive pathogens such as Listeria. The antagonistic substance was identified as macrocyclic peptide antibiotic micrococcin P1, which had previously not been reported for the genus Staphylococcus. Micrococcin P1, also a potent inhibitor of the malaria parasite Plasmodium falciparum, is structurally related to thiostrepton, thiocillins and nosiheptide. Although all of these peptide antibiotics have been known for quite a long time, their mode of biosynthesis had not been determined in detail yet. By using degenerated PCR, a gene fragment encoding a nonribosomal peptide synthetase (NRPS) could be amplified from S. equorum. The corresponding chromosomal locus was disrupted by insertional mutagenesis, and it could be shown that all mutants obtained displayed a micrococcin P1-deficient phenotype. Sequence analysis of a coherent 2.8-kb fragment revealed extensive homology to known NRPSs, and allowed the assignment of the domain organization 'condensation-adenylation-thiolation-condensation'; an arrangement predicted only for two loci within the presumably 14-modular, 1.6-MDa biosynthetic NRPS template. Biochemical characterization of the adenylation domain exhibited selectivity for the substrate amino-acid threonine. All of these data substantiate that the macrocyclic peptide antibiotic is biosynthesized nonribosomally, and provide the basis for the characterization of the entire biosynthetic gene cluster. The biosynthetic machinery of micrococcin will serve as a model system for structurally related, pharmacologically important pyridinyl polythiazole class peptide antibiotics. Furthermore, this knowledge will enable the manipulation of its NRPS template, which in turn may grant the targeted engineering of even more potent anti-listerial and anti-malaria drugs.
authors.affiliation: Institut für Mikrobiologie, FML Weihenstephan, Technische Universität München, Freising, Germany.
authors.forename: M C
authors.initials: MC
authors.lastname: Carnio
authors.forename: T
authors.initials: T
authors.lastname: Stachelhaus
authors.forename: K P
authors.initials: KP
authors.lastname: Francis
authors.forename: S
authors.initials: S
authors.lastname: Scherer
mesh_terms: D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000096:biosynthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001430:Bacteriocins; D001483:Base Sequence; D003001:Cloning, Molecular; D017931:DNA Primers; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D008087:Listeria / Q000187:drug effects; D008969:Molecular Sequence Data; D010453:Peptide Synthases / Q000235:genetics; D010455:Peptides; D011487:Protein Conformation; D012270:Ribosomes / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D013210:Staphylococcus / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D017931:DNA Primers; D010455:Peptides; C009779:micrococcin; D010453:Peptide Synthases